key: cord-0720882-s86oag32 authors: Goyal, Medha; Ray, Ishita; Mascarenhas, Dwayne; Kunal, Shekhar; Sachdeva, Ruchi Arora; Ish, Pranav title: Myocarditis post SARS-CoV-2 vaccination: a systematic review date: 2022-03-03 journal: QJM DOI: 10.1093/qjmed/hcac064 sha: cc19f7900964c5e5c9e46a479f66d976b493dc21 doc_id: 720882 cord_uid: s86oag32 BACKGROUND: Variable clinical criteria taken by medical professionals across the world for myocarditis following COVID-19 vaccination along with wide variation in treatment necessitates understanding and reviewing the same. OBJECTIVES AND METHODS: A systematic review was conducted to elucidate the clinical findings, laboratory parameters, treatment and outcomes of individuals with Myocarditis after COVID-19 vaccination after registering with PROSPERO. Electronic databases including MEDLINE, EMBASE, PubMed, LitCovid, Scopus, ScienceDirect, Cochrane Library, Google Scholar, Web of Science were searched. RESULTS: A total of 85 articles encompassing 2184 patients were analysed. It was a predominantly male (73.4%) and young population (Mean age 25.5 ± 14.2 years) with most having taken an mRNA-based vaccines (99.4%). The mean duration from vaccination to symptom onset was 4.01 ± 6.99 days. Chest pain (90.1%), dyspnoea (25.7%) and fever (11.9%) were the most common symptoms. Only 2.3% had comorbidities. CRP was elevated in 83.3% and cardiac troponin in 97.6% patients. An abnormal ECG was reported in 979/1313 (74.6%) patients with ST-segment elevation being most common (34.9%). Echocardiographic data was available for 1243 patients (56.9%) of whom 288 (23.2%) had reduced left ventricular ejection fraction. NSAIDS (76.5%), steroids (14.1%) followed by colchicine (7.3%) were used for treatment. Only 6 patients died among 1317 of whom data was available. CONCLUSION: Myocarditis following COVID-19 vaccination is often mild, seen more commonly in young healthy males and is followed by rapid recovery with conservative treatment. The emergence of this adverse event calls for harmonizing case definitions and definite treatment guidelines which require wider research. The details of various laboratory and radiological investigations have been summarized in Table 3 . Inflammatory markers such as CRP was elevated in 325/390 (83.3%) patients. An elevated cardiac troponin T/ troponin I was reported in 1330/1363 (97.6%) patients while elevated Brain natriuretic peptide (BNP) and NTpro BNP were observed in 24.5% and 65.6% patients each. An abnormal ECG was reported in 979/1313 (74.6%) patients with ST segment elevation in 342 (34.9%), T-wave inversion in 90 (9.2%), non-sustained ventricular tachycardia (NSVT) in 19 (1.9%), ventricular tachycardia (VT) and ventricular fibrillation (VF) in 1 (0.1%) patient each. Complete heart block and atrial fibrillation were reported in 2 (0.2%) patients each. LGE had a predominant sub-epicardial distribution in 169 (86.2%) patients followed by midmyocardial in 48 (24.5%) patients, subendocardial and transmural in 2 (1%) patients each. A diagnosis of definite myocarditis was established in (523; 39.1%), probable in (797; 59.5%) and possible myocarditis in (19; 1.4%). In the majority of cases, this was based on symptoms, raised cardiac biomarkers and cardiac imaging findings supportive of myocarditis. However, a subset of patients (11;0.5%) underwent histopathological evaluation based on EMB (8;0.37%) or autopsy (3;0.14%) specimens. Histopathological findings included lympho-histiocytic myocarditis in 8 (0.37%) while in three patients (0.14%) there was no evidence of inflammatory infiltrate. Additionally, eosinophilic infiltrate was observed in four patients (0.18%) while none had any evidence of myocyte necrosis. Eighty-three (7.1%) of the patients diagnosed with vaccine induced myocarditis were admitted into the ICU. Shock was reported in 23 (1.9%) patients during the course of hospital stay mandating cardiovascular support in the form of inotropes in 23 (1.9%), intra-aortic balloon pump [IABP] in 1 (0.08%) or extracorporeal membrane oxygenation [ECMO] in 3 (0.2%). NIV support was reported in 3 (0.2%) and mechanical ventilation in 4 (0.3%) patients. Table 4 summarizes the information regarding the treatment administered and the outcomes. A variety of anti-inflammatory therapies were used for the treatment of vaccine induced myocarditis including NSAIDS (891; 76.5%), steroids (164; 14.1%), colchicine (85; 7.3%), intravenous immunoglobulin (IVIG) (155; 13.3%) and biologics 3 (0.2%) such as Anakinra. Additional therapies included beta-blockers in 72 (6.2%), diuretics in 32 (2.7%), ACE inhibitors/ARBs in 51 (4.4%), ARNI in 3 (0.2%) patients. Concomitant antibiotic therapy was administered in 0.7% patients while 5.7% of the subjects' received anticoagulants. The mean duration of the hospital stay was 4.3+5.8 days. Data regarding the outcomes was available for 1317 subjects of whom 6 6 (0.5%) died during the course of hospital stay while 1311 (99.5%) were discharged from the hospital. This review describes the demographic profile, clinical features, diagnostics and therapeutics of the patients developing myocarditis post COVID-19 vaccination. Our results indicated that post-COVID-19 vaccine myocarditis was more prevalent among young males with the majority of reported cases being below 20 years of age. The predilection for younger age could be due to stronger immune responses seen in this age group as compared to adults. Studies have reported that the levels of proinflammatory cytokines such as TNF-alpha and IFN-gamma often increase at puberty and decline thereon. 96 Additionally, gender differences could be due to varying effects of sex hormones on the immune system. Testosterone has been shown to lead to a stronger cellular immune response mediated by Th1 cells while estrogen has an inhibitory effect on the pro-inflammatory T cells. 97 These are significant observations as vaccination drives are being launched across the globe to enhance coverage, especially among children and adolescents. Awareness of this possible complication amongst medical professionals and the vaccination beneficiaries is crucial for seeking early medical attention. The apparent predilection for caucasian race noted in our review requires watchful consideration as vaccine coverage improves and data emerges from other parts of the globe. Another striking observation in our review was that myocarditis occurred more frequently following administration of mRNA vaccines (99.4%) especially after the second dose (83.2%). While it may be a reporting bias or possibly be due to the greater global coverage by mRNA vaccines, there is always a chance of pathophysiological links which needs to be explored. mRNA vaccines have a nucleoside-modified mRNA which encodes the viral spike glycoprotein of SARS-CoV-2. This viral spike protein then incites an adaptive immune response to identify and thereby neutralize the future infections with the virus. mRNA molecules can itself be immunogenic and the nucleoside modification tends to lower the innate immunogenicity with less production of inflammatory cytokines. 98 However, in individuals with certain genetic 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 predispositions, the immune system might detect mRNA as an antigen leading to an inflammatory cascade with production of pro-inflammatory cytokines and development of myocarditis. 99 Other probable mechanisms of hyperimmunity include molecular mimicry by antibodies to SARS-CoV-2 spike proteins which cross-react with myocardial contractile proteins such as α-myosin and the possible role of natural killer (NK) cells. 100 These hypotheses are also supported by the fact that a majority of cases of COVID-19 vaccine induced myocarditis occurred following administration of the second dose of the vaccine. However, further research dwelling into plausible mechanisms of myocardial injury is of paramount importance to understand the clinico-pathophysiology and tailoring the therapeutics. A possibility of COVID-19 vaccine induced myocarditis should be considered among individuals developing chest pain, dyspnoea or fever within 3-4 days following vaccination. A diagnosis is often established based on clinical presentation and supplemented by elevated levels of cardiac biomarkers and supportive cardiac imaging. EMB, despite being the gold standard, has been sparingly used for the diagnosis of vaccine induced myocarditis due to its invasive nature. for a condition of mild nature with a conservative treatment approach. 101 In our review, EMB was performed in only 0.37% of patients with the majority of them having lympho-histiocytic infiltration in the myocardium. A diagnosis of vaccine induced myocarditis can often be challenging in individuals with recent SARS-CoV-2 infection hence, protocols for testing for recent COVID-19 infection to eliminate its confounding effect should be in place. Cardiac imaging using echocardiography and CMR plays an important role in assessment of cardiac functions and morphology in patients with myocarditis. CMR not only helps in establishing the diagnosis of myocarditis but also excludes confounding abnormalities. The diagnosis of myocarditis on CMR is often established based on the revised Lake Louise criteria. 102 In our review, classical CMR findings of myocarditis viz. LGE and myocardial oedema were reported in 80.7% and 63.3% patients respectively. A majority of patients had a sub-epicardial distribution of LGE, a feature consistent with that of myocarditis. A majority of patients were categorized as definite/probable myocarditis (98.6%) while possible myocarditis was reported in 1.4 % patients. The treatment of myocarditis following COVID-19 vaccination is highly variable, probably due to absence of defined guidelines as well as regional preferences, varying severity and clinical presentation. Overall, the therapeutic approach for symptomatic patients includes the use of NSAIDS and/or colchicine. Corticosteroids, IVIg and immunomodulators such as TNF-alpha inhibitors are often reserved for severe cases. Findings from our review too suggested that NSAIDS were the most common treatment modality, followed by colchicine and steroids. An important grey zone in the treatment strategy is the determination of need for hospitalization or intensive care. Most of the cases of vaccine induced myocarditis were mild in nature with only 8.7% of them requiring ICU stay. Findings of our review suggested that clinical outcomes of vaccine-associated myocarditis were mostly very favourable with mortality reported in 1.4% of subjects while the rest of them had rapid spontaneous recovery. It is important to conclude that despite the alarming nature of this rare adverse event, it should not be a deterrent to mass vaccination as most of the patients had favourable outcomes with rapid recovery following therapy with oral anti-inflammatory agents and a short hospital stay. The risk-benefit ratio of vaccination unanimously favours the use of COVID-19 vaccines which prevents severe forms of infection, reduces risk of hospitalization, ICU admissions and death in both young and elderly age groups. 103 Large data registries and clinical cohorts are needed to strengthen diagnostic criteria, risk stratification and therapeutic approaches for vaccine induced myocarditis. Till larger evidence emerges, the vaccine coverage should continue globally albeit the fear of myocarditis. However, prospective research should continue to systematically document this adverse event alongside, especially in the current scenario where boosters have entered the ball game, to strengthen our understanding of the precise nature of this condition. Our systematic review on COVID-19 vaccine induced myocarditis had a few limitations. This study is mainly descriptive including primarily case reports and case series due to which the level of evidence is low. Additionally, due to the inclusion of multiple studies, there is a risk of reporting bias. Vaccine inequity across the world and the availability of certain vaccines in different countries makes it difficult to evaluate and compare regional variations in occurrence and severity of myocarditis. Myocarditis following COVID-19 vaccination has the potential to spark fear and vaccine hesitancy. There is a need to understand that myocarditis following COVID-19 vaccination is often mild, more commonly diagnosed in young healthy adults after 2nd dose of mRNA vaccine, is acute in onset followed by rapid recovery with conservative treatment. There is a need for prompt recognition of Myocarditis in order to limit the hyperinflammatory response and prevent poor outcomes. The emergence of this adverse event calls for harmonizing case definitions for establishing a correct diagnosis as well as definite treatment guidelines. This would largely be possible through wider research, collaborative efforts and development of data registries and clinical cohorts. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 31 Tailor et al 41 n=1/ 44 years Moderna/ 2nd Dyspnoea, chest 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 https://mc.manuscriptcentral.com/qjm Manuscripts submitted to QJM: An International Journal of Medicine 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 https://mc.manuscriptcentral.com/qjm Manuscripts submitted to QJM: An International Journal of Medicine 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 https://mc.manuscriptcentral.com/qjm Manuscripts submitted to QJM: An International Journal of Medicine 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 Symptomatic Acute Myocarditis in 7 Adolescents After Pfizer-BioNTech COVID-19 Vaccination Acute Myopericarditis after COVID-19 Vaccine in Teenagers. Case Rep Cardiol Temporal association between the COVID-19 Ad26.COV2.S vaccine and acute myocarditis: A case report and literature review Acute Myocarditis Following COVID-19 mRNA Vaccination in Adults Aged 18 Years or Older Biopsy-proven lymphocytic myocarditis following first mRNA COVID-19 vaccination in a 40-year-old male: case report Myocarditis following COVID-19 vaccination Transient Cardiac Injury in Adolescents Receiving the BNT162b2 mRNA COVID-19 Vaccine Myocarditis Following COVID-19 Vaccination Self-limited myocarditis presenting with chest pain and ST segment elevation in adolescents after vaccination with the BNT162b2 mRNA vaccine. Cardiol Young Myocarditis and Pericarditis After Vaccination for COVID-19 COVID-19 mRNA Vaccine and Myocarditis Multisystem inflammatory syndrome in a male adolescent after his second Pfizer-BioNTech COVID-19 vaccine Myocarditis After BNT162b2 and mRNA-1273 Vaccination Acute Myocarditis Following mRNA-1273 SARS-CoV-2 Vaccination. CJC Open Myopericarditis in a previously healthy adolescent male following COVID-19 vaccination: A case report Myocarditis following mRNA vaccination against SARS-CoV-2, a case series IL-6-Interleukin-6, IvIG-Intravenous Immunoglobulin, EF-Ejection fraction, ESR-Erythrocyte sedimentation rate, LDH-Lactate dehydrogenase, ALT-Alanine transaminase, AST-Aspartate transaminase, LVEF-. Left ventricular ejection fraction, LGE-Late Gadolinium Enhancement, CT-computed tomography, GGO-Ground glass opacities Trop T: Reference normal ≤0.014 ng/mL